The FDA has accepted for review the supplemental biologics license application for Dupixent for the treatment of chronic spontaneous urticaria, Regeneron Pharmaceuticals and Sanofi announced in a press release. The application indicates Dupixent (dupilumab), a fully monoclonal antibody that blocks the shared receptor component for interleukin (IL)-4 and IL-13, for patients aged 12 years and older
The SLE Severe Infection Score-Revised, an updated score for predicting severe infections in systemic lupus erythematosus, is more accurate and feasible than the prior version,…
People who vaped and smoked cigarettes appeared four times more likely to develop lung cancer compared with those who only smoked, according to study results…
Preparing for her 2024 to 2025 term as American Thoracic Society president, Irina Petrache, MD, ATSF, plans to make sure the society is at the…
Michael J. Hall, MD, MS, FASCO, must occasionally remind himself not everyone holds genetics research in the high esteem he does.He recalled a middle-aged African…
SAN DIEGO — Patients with COPD treated with targeted lung denervation along with optimal COPD therapy experienced fewer exacerbations over 2 years, according to research…
SAN DIEGO — Fewer patients with sepsis receiving acetaminophen vs. placebo developed acute respiratory distress syndrome, according to research presented at the American Thoracic Society…
The FDA approved Yesafili and Opuviz as the first interchangeable biosimilars to Eylea, according to a press release from the FDA.
Tailored ablation guided by AI was linked to better 1-year outcomes than pulmonary vein isolation alone for patients with persistent atrial fibrillation, according to the…
In a real-world registry of patients with atrial fibrillation treated with a pulsed field ablation catheter, the system was associated with favorable 30-day outcomes, researchers…
A system including a leadless pacemaker and a subcutaneous implantable cardioverter defibrillator that wirelessly communicate with each other was safe in patients at risk for…
